IRIS
TROIANI, Teresa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 13.659
NA - Nord America 8.392
AS - Asia 5.678
SA - Sud America 852
Continente sconosciuto - Info sul continente non disponibili 520
AF - Africa 84
OC - Oceania 22
Totale 29.207
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 8.742
US - Stati Uniti d'America 8.165
SG - Singapore 1.982
IT - Italia 1.453
IE - Irlanda 1.237
CN - Cina 1.203
HK - Hong Kong 868
VN - Vietnam 684
BR - Brasile 683
GB - Regno Unito 475
DE - Germania 468
UA - Ucraina 353
KR - Corea 319
FR - Francia 274
IN - India 163
FI - Finlandia 139
SE - Svezia 127
CA - Canada 123
JP - Giappone 122
GR - Grecia 109
TR - Turchia 90
NL - Olanda 70
AR - Argentina 62
BD - Bangladesh 47
PK - Pakistan 45
MX - Messico 38
AT - Austria 35
EC - Ecuador 33
BE - Belgio 31
ID - Indonesia 31
PL - Polonia 29
CO - Colombia 27
ES - Italia 26
IQ - Iraq 22
ZA - Sudafrica 21
LT - Lituania 20
CZ - Repubblica Ceca 19
MA - Marocco 17
CR - Costa Rica 16
AU - Australia 14
CH - Svizzera 11
CL - Cile 11
VE - Venezuela 11
AZ - Azerbaigian 10
IL - Israele 10
PH - Filippine 9
GT - Guatemala 8
IR - Iran 8
JM - Giamaica 8
NZ - Nuova Zelanda 8
PE - Perù 8
TH - Thailandia 8
TN - Tunisia 8
HN - Honduras 7
KE - Kenya 7
PY - Paraguay 7
EE - Estonia 6
NP - Nepal 6
UZ - Uzbekistan 6
AE - Emirati Arabi Uniti 5
BJ - Benin 5
BO - Bolivia 5
EG - Egitto 5
JO - Giordania 5
KG - Kirghizistan 5
RO - Romania 5
SA - Arabia Saudita 5
AL - Albania 4
DO - Repubblica Dominicana 4
HU - Ungheria 4
KZ - Kazakistan 4
MK - Macedonia 4
MY - Malesia 4
SN - Senegal 4
TT - Trinidad e Tobago 4
UY - Uruguay 4
BH - Bahrain 3
BY - Bielorussia 3
DZ - Algeria 3
ET - Etiopia 3
SV - El Salvador 3
VG - Isole Vergini Britanniche 3
AG - Antigua e Barbuda 2
BG - Bulgaria 2
BS - Bahamas 2
DK - Danimarca 2
EU - Europa 2
GA - Gabon 2
GI - Gibilterra 2
LK - Sri Lanka 2
LV - Lettonia 2
NG - Nigeria 2
NI - Nicaragua 2
PR - Porto Rico 2
TW - Taiwan 2
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BN - Brunei Darussalam 1
Totale 28.664
Salva come PNG Salva come JPEG
Città #
Moscow 3.126
Dublin 1.222
San Jose 1.149
Singapore 866
Hong Kong 849
Santa Clara 817
Chandler 669
Ashburn 654
Jacksonville 565
Council Bluffs 504
Seoul 297
Beijing 225
Naples 214
Ho Chi Minh City 212
New York 195
Milan 187
Hanoi 164
Princeton 163
Dallas 161
Hefei 160
Bremen 138
Los Angeles 136
Roxbury 129
Medford 121
Ann Arbor 120
Munich 103
The Dalles 93
Bengaluru 84
Caserta 79
São Paulo 75
Wilmington 75
Boardman 69
Chicago 57
Cambridge 48
Nanjing 48
Des Moines 44
San Mateo 43
Da Nang 40
Woodbridge 38
North Charleston 37
Rome 37
Turku 37
Haiphong 36
Miano 36
Amsterdam 34
Elora 34
Napoli 34
Nuremberg 33
Atlanta 32
Brooklyn 30
Brussels 29
Houston 28
Warsaw 27
Rio de Janeiro 26
Tokyo 24
Montreal 23
Dong Ket 22
Orem 22
Shanghai 22
Tianjin 22
Aversa 21
Frankfurt am Main 21
Hải Dương 19
Vienna 19
Brasília 17
Columbus 17
Falkenstein 17
Mountain View 17
North Bergen 17
Norwalk 17
Brno 16
Manchester 16
Toronto 16
Nanchang 15
San Francisco 15
Buffalo 14
Chennai 14
Helsinki 14
Las Vegas 14
London 14
Rawalpindi 14
Bogotá 13
Boston 13
Denver 13
Hangzhou 13
Jakarta 13
Lappeenranta 13
Phoenix 13
Piscataway 13
Seattle 13
Thái Bình 13
Belo Horizonte 12
Bologna 12
Changsha 12
Jinan 12
Madrid 12
San José 12
Curitiba 11
Düsseldorf 11
Ercolano 11
Totale 15.143
Salva come PNG Salva come JPEG
Nome #
Comparative study of NGS platform ion torrent personal genome machine and therascreen rotor-gene Q for the detection of somatic variants in cancer. 262
Beyond N staging in colorectal cancer: Current approaches and future perspectives 239
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 221
ONCOLOGIA MEDICA 215
AXL is an oncotarget in human colorectal cancer 205
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC? 203
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 201
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 200
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 200
A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells 199
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 195
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 190
Microsatellite Status Detection in Gastrointestinal Cancers: PCR/NGS Is Mandatory in Negative/Patchy MMR Immunohistochemistry 190
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 189
A preliminary study for quantitative assessment with HFUS (High-frequency ultrasound) of nodular skin melanoma breslow thickness in adults before surgery: Interdisciplinary team experience 188
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 187
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 186
Metabolomic approach for a rapid identification of natural products with cytotoxic activity against human colorectal cancer cells 184
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 182
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 177
Small Bowel Metastasis in a Stage IV Melanoma Patient: A Report of Multimodal Approach 177
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 175
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 174
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor 173
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 173
Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial 172
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 172
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 171
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors 171
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 171
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 169
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 168
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 168
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 168
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 167
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 167
Cytologic diagnosis of metastatic melanoma by FNA: A practical review 167
Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer 167
Cetuximab rechallenge in molecularly selected metastatic colorectal cancer: the randomized CAVE-2 GOIM trial 165
antitumor activity of zd6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor in combination with SC-236, a cicloxigenase-2 inhibitor 165
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 163
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial 163
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations 163
Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer 162
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 162
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 161
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 161
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 160
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 160
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 159
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 155
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy 155
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 154
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors 153
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 152
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial 152
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 152
Antiangiogenic drugs in non small cell lung cancer treatment 150
Pimasertib hydrochloride 149
Panitumumab plus trifluridine/tipiracil as anti‐EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial 148
Farmacogenomica e cancro colorettale 148
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 147
Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass 147
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: A case report and a review of literature 147
The potential diagnostic and predictive role of anaplastic lymphoma kinase (ALK) gene alterations in melanocytic tumors 146
The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review 145
To Get the Most out of the Least: BRAF Molecular Evaluation in Melanoma Metastases on Cell Suspension from Fine Needle Aspiration Cytology Needle Rinses 145
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. 145
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells 144
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 144
PRAME Immunocytochemistry for the Diagnosis of Melanoma Metastases in Cytological Samples 144
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer 142
Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines 142
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 142
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 142
TRASTUZUMAB RESISTANCE IN BREAST CANCER 141
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 140
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer 139
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 139
Adipose-tumor crosstalk in colorectal cancer: Identifying (Epi)genetic biomarkers for tumor progression and cachexia 138
Application of CytoMatrix for the diagnosis of melanoma metastases on FNA cytology samples: Performance of a novel cell block method 138
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 138
Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: A retrospective analysis 137
Immunotherapy in advanced anal cancer: Is the beginning of a new era? 137
Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment 137
Genetic Landascape of Primary versus metastatic colorectal cancer: to what extent are they concordant ? 136
Prevention of cardiovascular complications in elderly cancer patients 135
Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma 134
Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases 133
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study 133
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next generation sequencing: findings from the CAPRI-GOIM trial. 132
NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): From clinical trials to clinical practice 132
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 132
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 132
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 132
Targeting EGFR in Pancreatic Cancer Treatment. 131
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 131
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 131
Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? 131
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 131
Totale 16.087
Salva come PNG Salva come JPEG
Categoria #
all - tutte 100.976
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 100.976
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.053 0 0 0 25 340 25 37 35 57 90 120 324
2022/20232.567 255 56 46 237 283 233 10 158 1.150 14 71 54
2023/20241.111 102 49 40 67 329 171 33 33 21 16 86 164
2024/20253.522 61 93 47 139 527 462 453 328 466 379 308 259
2025/202615.251 609 716 748 734 1.213 8.144 809 791 642 416 260 169
2026/20272.808 139 476 1.119 1.074 0 0 0 0 0 0 0 0
Totale 29.207